Plain-English translation of NCT06333561 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a real-world study looking at whether combining three treatments — , a PD-1 inhibitor (an immunotherapy), and hepatic arterial infusion chemotherapy (a special way to deliver chemotherapy directly to the liver) — works better than alone for people with a specific type of advanced liver cancer called infiltrative hepatocellular carcinoma. The researchers will collect and analyze information from patients receiving these treatments as part of their standard care to understand how effective and safe this combination is.
Infiltrative hepatocellular carcinoma is a particularly aggressive form of liver cancer that is hard to treat. Doctors believe that combining multiple treatments — rather than using one drug alone — might work better, but they need real-world data from actual patients to confirm whether this combination truly helps people live longer and improves their quality of life.
You likely qualify if…
You likely don't qualify if…
You would continue receiving your cancer treatment as usual — either the three-drug combination or alone — while the research team collects information from your medical visits, imaging scans, and lab tests. The study involves no extra procedures beyond your regular care. The researchers will track how well the treatment works, how you tolerate it, and your outcomes over time, building a database that helps answer important questions about the best way to treat this type of cancer.
AI-generated summary from trial data · Jun 29, 2026 · Not medical advice
China
Sponsor
Sun Yat-sen University
Enrollment target
~300 participants
Started
January 2021
Primary completion
December 2024
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Qunfang Zhou, MD
Chinese PLA General Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.